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METHODS: Clinical data from 79 PD patients and data
from the literature regarding PD-related costs, clinical
progression and life expectancy were used to develop a
disease progression model according to the Hoehn and
Yahr stage of PD (HY). The model was designed to model
both protective and symptomatic treatment effects. Out-
comes were based on a consecutive series of 14 PD
patients treated with intrastriatal NT of human embry-
onic mesencephalic tissue, and followed for 2–10 years
thereafter. Since the majority of patients receiving NT had
early onset PD and were in HY 3–4, the cost-effectiveness
of NT was evaluated for patients belonging to these cat-
egories. Costs and quality adjusted life years (QALY)
were calculated for a period of 25 years and discounted
at 3%. The calculations were made in Euro (€) (2002
prices). A sensitivity analysis was performed where sce-
narios regarding treatment effect, time horizon, discount
rate, and the procedure cost were altered. RESULTS:
Patients with a preoperative HY state of 3 and 4
improved 0.552 and 0.736 HY stages following NT,
which is equivalent to 4.9 and 6.6 years in less advanced
PD stages, respectively. The cost of NT, including
expected costs of complications, was €36,000. The incre-
mental cost-effectiveness ratio of NT compared to stan-
dard treatment was €11,400 for patients in HY 3 and cost
saving in HY 4 patients. CONCLUSIONS: According to
the assumptions made in the model, NT is cost-effective
compared to standard treatment in Sweden. The main
conclusions were insensitive to the assumptions made in
the sensitivity analysis.
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OBJECTIVES: Parkinsonian syndromes (PS) can be difﬁ-
cult to diagnose clinically, the most common condition
misdiagnosed as PS being essential tremor (ET).
DaTSCAN (123I-FP-CIT) SPECT imaging accurately 
differentiates PS with dopaminergic deﬁcit from ET 
in patients with uncertain clinical diagnosis (sensitivity
95%, speciﬁcity 93%). This study aimed to assess the eco-
nomic value of using DaTSCAN to the Belgian Health
care system. METHODS: A Markov model was devel-
oped to simulate a cohort of patients with clinically
uncertain PS managed over 5 years 1) without DaTSCAN
(treatment based on clinical judgement), or 2) all patients
receiving DaTSCAN at the outset. Health states were
deﬁned by type of therapy (PS ﬁrst-line, PS second-line,
ET, none) and underlying condition (PS, ET). The model
estimated time on appropriate therapy (PS therapy for
underlying PS, ET therapy for underlying ET) and patient
management costs. Model inputs were from published
studies, with treatment patterns/resource use from a
Delphi panel of 13 Belgian physicians. 53% cohort
members were assumed to have true PS. Costs were from
ofﬁcial sources, the test cost (agent plus administration)
being €900. RESULTS: Without DaTSCAN, 41% of
cohort members were treated appropriately at the outset,
rising to 75% at 5 years. Using DaTSCAN, 94% of
patients were treated appropriately at the outset, declin-
ing to 77% at 5 years. DaTSCAN use generated an incre-
mental 1.40 “adequately treated years” at a net cost of
€140 per patient. This result was sensitive to the under-
lying prevalence of PS, but relatively robust to variations
in other model parameters, such as rates of adverse events
and withdrawal from therapy. CONCLUSION: Treat-
ment of patients with clinically uncertain PS based on
DatSCAN rather than clinical judgement may be consid-
ered to be an economically favourable strategy. An
increase in time on appropriate therapy is achieved at
modest extra cost to the Health care system.
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The management of a chronic disease must integrate the
needs induced by the disease on the patient’s surround-
ings. OBJECTIVE: The TRILOGIE study was initiated by
a group of neurological and neuro-paediatric experts and
the Ligue Francaise Contre l’Epilepsie to study the Child-
Parent-Epilepsy interaction. The objective is to assess the
socio-economic consequences of epilepsy on the daily life
of the parents of a child diagnosed as epileptic for more
than six months. METHODS: Self-administered ques-
tionnaires, created on the basis of interviews with fami-
lies of epileptic children, were sent to paediatricians and
neuro-paediatricians taking care of epileptic children, as
well as to members of patients’ associations. They then
distributed them to the parents of the children concerned.
RESULTS: The results concerned a population of 668
parents of epileptic children. Eight domains were
explored as part of the study. The management of the
disease is often difﬁcult with more than one hospitalisa-
tion (70% of the children). The consequences for the chil-
dren are serious difﬁculties at school (40%) and a greater
need for care (63%). Medical and/or psychological help
is therefore often needed by the parents (38%). Epilepsy
is source of conﬂict for 43% of the couples. The major
economic impact of the disease is due to partial reim-
bursement of nursing costs, extra costs of care and
schooling and loss of revenue due to one parent giving up
full time work. CONCLUSIONS: TRILOGIE underlines
the parent’s need for information concerning: the current
and future treament of the disease, the possibilities of sco-
larisation and the concrete daily help.
